Gastric Modulator (TANTALUS® System) Versus Insulin Treatment in Obese Type 2 Diabetic Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-10-31

Study Completion Date

2011-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to analyze the pre- and post-operative clinical, hormonal and biochemical changes in moderately obese type 2 diabetic patients who are sub-optimally controlled on at least 2 anti-diabetic agents. Study participants will either receive implantation of the gastric contraction modulator or conventional treatment with insulin therapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Oral GLP1RA RGT001-075 in Adults With Type 2 Diabetes

NCT05297045

Type 2 Diabetes Mellitus

TERMINATED PHASE2

Study of Recombinant Human Insulin-Like Growth Factor I in Patients With Severe Insulin Resistance

NCT00004419

Insulin Resistance Hyperglycemia

COMPLETED NA

Surgical Treatment of Type 2 Diabetes in Non-Morbidly Obese Patients

NCT00596973

Diabetes

WITHDRAWN PHASE4

Antrum Size, Glucagon-like Peptide 1 Levels and Glycemic Control After Sleeve Gastrectomy in Morbid Obese Diabetic Adolescents

NCT04388059

Adolescent Obesity

COMPLETED

Effect of Liraglutide on Glucagon Secretion in Subjects With Type 2 Diabetes

NCT01509742

Diabetes Diabetes Mellitus, Type 2

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes Mellitus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Tantalus

The TANTALUS System is implanted using minimally invasive procedure (laparoscopy). It uses leads with stitch electrodes to deliver electrical signals to the gastric wall for the treatment of obese subjects with T2DM. The device is intended to improve glycemic control and induce weight loss.

Group Type EXPERIMENTAL

Tantalus

Intervention Type DEVICE

The TANTALUS System is implanted using minimally invasive procedure (laparoscopy). It uses leads with stitch electrodes to deliver electrical signals to the gastric wall for the treatment of obese subjects with T2DM.

Control

Insulin treatment will be prescribed, in accordance with the common medical practice at the institute. Dosages will be recorded on a daily basis.

Group Type ACTIVE_COMPARATOR

Insulin

Intervention Type DRUG

Insulin treatment will be prescribed, in accordance with the common medical practice at the institute. Dosages will be recorded on a daily basis.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tantalus

The TANTALUS System is implanted using minimally invasive procedure (laparoscopy). It uses leads with stitch electrodes to deliver electrical signals to the gastric wall for the treatment of obese subjects with T2DM.

Intervention Type DEVICE

Insulin

Insulin treatment will be prescribed, in accordance with the common medical practice at the institute. Dosages will be recorded on a daily basis.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Able to provide written informed consent
* Adult patients aged between 18 and 60 years (inclusive)
* Male or female of Chinese ethnicity
* Type 2 diabetes mellitus with disease duration of greater than 2 and less than 10 years
* severe obesity, includes BMI 25 to 27.5 kg/m and central obesity defined by waist circumference greater than 90 cm in women and greater than 95 in men, or BMI greater than 27.5 to less than 35 kg/m
* HbA1c greater than or equals to 7.5% but less than 10% despite treated with maximum dose or maximally tolerated dose of 2 anti-diabetic drugs (OAD) with good drug compliance

Exclusion Criteria

* On anti-obesity drugs
* On insulin treatment at the time of the recruitment
* On glitazone or incretins (dipeptidyl peptidase-4 inhibitor or glucagons-like peptide-1) treatment
* On any implantable device including cardiac pacing
* Anticipated to have MRI examinations
* Fasting C-peptide level less than 0.5g/L
* Renal impairment (defined as serum creatinine greater than 150mol/L and/or estimated glomerular filtration rate less than 60 mL/min/1.73m)
* Significant liver impairment (ALT more than 3 times upper limit of normal range)
* Active malignant disease. Patients with malignant disease who have been disease-free for at least 5 years are eligible
* Active infection
* Active and uncontrolled thyroid diseases
* Childbearing age female patients without reliable contraceptive methods
* Life expectancy less than 12 months
* Administration of another investigational drugs or procedures within 4 weeks before screening
* Any medical illness or condition as judged by the investigators as ineligible to participate the study
* Special population, e.g. prisoner, mentally disabled, investigators' student or employees

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No